Wegovy FDA Approval History
Last updated by Judith Stewart, BPharm on June 8, 2021.
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are overweight (BMI ≥27 kg/m2) or obese (BMI ≥30 kg/m2).
Development Timeline for Wegovy
|Jun 4, 2021||Approval FDA Approves Wegovy (semaglutide) to Treat Adults with Obesity|
|Mar 23, 2021||Adults with Obesity Treated with Semaglutide 2.4 mg Achieved and Maintained a Significant Amount of Weight Loss in a 68-Week Trial|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.